US Patent 10,342,791: Tafenoquine Malaria-Prophylaxis Claims, Scope, Expiration, and Patent Landscape
US Patent 10,342,791 is a method-of-use patent directed to tafenoquine-based prevention of symptomatic Plasmodium falciparum malaria. Its commercial center is the 200 mg loading regimen followed by weekly exposure dosing, with optional post-exposure dosing. The broadest independent method claim requires a defined dose sequence, pharmacokinetic threshold, malaria-naive and G6PD-normal subjects, and administration before and during potential malaria exposure. Claim 20 separately protects a kit containing initial and exposure doses with instructions.
The patent is materially relevant to tafenoquine prophylaxis products, including Arakoda, but it does not cover every tafenoquine use. It does not claim the tafenoquine molecule generally, all tafenoquine formulations, radical-cure treatment of P. vivax, or every malaria-prevention regimen.
What drug and therapeutic use does US 10,342,791 protect?
Formula (I) is tafenoquine, generally administered as tafenoquine succinate. Tafenoquine is an orally active 8-aminoquinoline antimalarial. The claimed use is prevention of symptomatic P. falciparum malaria in malaria-naive, G6PD-normal human subjects.
The patent focuses on maintaining a minimum serum or plasma tafenoquine concentration of at least approximately 80 ng/mL. The dosing architecture is:
- Two or more initial doses over one to seven days.
- At least the first initial dose before potential exposure.
- One or more exposure doses per week during potential exposure.
- Optional post-exposure dosing after exposure risk ends.
The commercial regimen most closely aligned with claim 30 is 200 mg once daily for three days before exposure, 200 mg once weekly during exposure, and 200 mg once after exposure ends. The FDA-approved Arakoda label uses a closely corresponding regimen for malaria prophylaxis in adults and adolescents weighing at least 45 kg [2].
What is the role of the 80 ng/mL Cmin limitation?
The 80 ng/mL limitation is a pharmacokinetic result limitation. Claim 1 requires the specified regimen to produce a Cmin concentration of at least approximately 80 ng/mL before exposure and substantially maintain that concentration during exposure in more than 50% of treated individuals.
Claim 15 raises the population requirement to at least 95%. Claim 31 applies the concentration requirement to the individual human subject rather than expressly repeating the population percentage.
This limitation narrows the claim but creates an infringement and validity issue. A challenger could contest:
- whether Cmin is measured in serum or plasma;
- the sampling time and assay methodology;
- what “substantially maintain” means;
- whether the relevant analysis is population-based or individual-based;
- whether a generic label would instruct physicians to achieve the claimed concentration; and
- whether the specification adequately supports all dose combinations across the claimed concentration range.
The concentration limitation may also complicate ANDA litigation because a generic applicant could attempt to characterize the claim as requiring a result that is not directly specified in the product label.
How are the claims organized?
Independent method claim 1
Claim 1 is the principal scope-defining claim. It requires all of the following:
| Limitation |
Requirement |
| Disease |
Prevention of symptomatic P. falciparum malaria |
| Patient |
Human, malaria-naive, G6PD-normal |
| Initial dosing |
At least two doses over one to seven days |
| Timing |
At least the first initial dose before potential exposure |
| Initial dose size |
Approximately 100 mg to 275 mg per dose |
| Initial total |
Approximately 500 mg to 900 mg combined |
| Exposure dosing |
One or more times per week during exposure |
| Exposure total |
Approximately 100 mg to 275 mg per week |
| Pharmacokinetics |
Cmin of at least approximately 80 ng/mL |
| Population performance |
Concentration substantially maintained in more than 50% of subjects |
The claim is therefore a regimen claim, not a compound claim. A product may contain tafenoquine and still avoid claim 1 if it is used outside the claimed patient population, dose sequence, timing, weekly exposure amount, or pharmacokinetic result.
Dependent claims 2 through 19
Claims 2 through 19 narrow the regimen in different directions.
The commercially important subset is:
- Claim 2: 200 mg daily for three days, followed by 200 mg weekly.
- Claim 4: initial doses once daily for three days.
- Claim 5: 200 mg for each initial dose.
- Claim 6: 200 mg total per week during exposure.
- Claim 7: exposure dosing once weekly.
- Claim 15: maintenance of the 80 ng/mL Cmin in at least 95% of the population.
- Claims 16 and 17: adult and child populations.
- Claim 18: oral or sublingual administration.
- Claim 21: tafenoquine succinate.
- Claims 23 and 24: broader weekly frequency and a 150 mg loading regimen.
Claims 12 through 14 address lower-body-weight or younger subjects. Claim 14 is particularly relevant to pediatric or low-weight dosing because it recites approximately 80 mg to 100 mg once daily for six days, followed by approximately 20 mg to 40 mg daily.
Claim 19 narrows the combined initial dose to approximately 525 mg to 585 mg. This limitation does not correspond exactly to the 600 mg total in the 200 mg for three days regimen, so it protects a different loading-dose range.
Claim 20: kit claim
Claim 20 covers a kit containing:
- at least two initial doses of approximately 100 mg to 270 mg;
- multiple exposure doses totaling approximately 100 mg to 275 mg per week; and
- instructions for the pre-exposure and exposure dosing sequence.
The kit claim does not expressly reproduce every limitation of method claim 1. In particular, the supplied claim language does not expressly require the malaria-naive, G6PD-normal population or the 80 ng/mL Cmin result. That difference may make claim 20 commercially important for packaged prophylaxis products and patient-use kits.
The kit must still be analyzed under ordinary claim-construction principles. A package containing tafenoquine tablets without instructions for the claimed regimen may present a different infringement profile from a kit expressly labeled for the patented schedule.
Claims 21 through 31: salt, post-exposure, and population refinements
Claim 21 expressly identifies tafenoquine succinate. Claim 22 covers a tafenoquine salt or salt structure, although the chemical structure is not reproduced in the supplied text.
Claims 25 through 30 add post-exposure dosing within one to ten days after exposure risk ends. Claim 30 recites the most commercially recognizable full regimen:
- 200 mg daily for three days before exposure;
- 200 mg weekly during exposure; and
- 200 mg once after exposure.
Claims 26 through 29 cover single or split post-exposure doses totaling approximately 150 mg to 300 mg.
What regimen does the patent most directly cover?
The strongest commercial overlap is the following regimen:
| Treatment stage |
Claimed dose |
| Loading day 1 |
200 mg |
| Loading day 2 |
200 mg |
| Loading day 3 |
200 mg |
| During exposure |
200 mg once weekly |
| After exposure |
200 mg once |
This regimen is covered most directly by claims 2, 4, 5, 6, 7, 21, and 30, assuming the patient and pharmacokinetic limitations are satisfied.
The broad claim also reaches alternatives such as:
- 150 mg loading doses administered four times;
- 165 mg, 180 mg, 210 mg, 240 mg, or 270 mg initial doses;
- daily exposure doses of 25 mg or approximately 30 mg;
- exposure dosing one to seven times per week;
- six-day lower-dose loading schedules;
- weight-based dosing of approximately 1 mg/kg to 5 mg/kg.
The use of “about” broadens the practical range but introduces claim-construction questions. Courts generally assess “about” in light of the specification, relevant technology, and expected measurement variation. A product using a nominal dose just outside a recited range may still create infringement risk if the specification supports a broader technical meaning.
When does US 10,342,791 lose exclusivity?
US 10,342,791 issued on July 9, 2019. Public patent records identify a 2015 priority date and a 2016 international filing basis. On a conventional 20-year term calculation from the relevant international filing date, the nominal expiration is in 2036, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any USPTO correction.
| Event |
Date |
| Earliest reported priority |
2015 |
| International or PCT filing basis |
2016 |
| US patent grant |
July 9, 2019 |
| Nominal 20-year term endpoint |
2036 |
| Patent-term adjustment |
Must be checked in the USPTO patent record |
| Patent-term extension |
No extension should be assumed without an FDA and USPTO record |
The patent’s practical exclusivity period is not identical to product exclusivity. FDA approval, Orange Book listing, regulatory exclusivity, other tafenoquine patents, and any litigation settlement can affect generic entry.
What is the Orange Book status of the patent?
The relevant FDA product is tafenoquine succinate, marketed as Arakoda by 60 Degrees Pharmaceuticals, LLC. Arakoda was approved under NDA 210795 for prevention of malaria in patients aged 18 years and older [2].
A method-of-use patent can be listed in the Orange Book when it claims an approved use of the approved drug. If US 10,342,791 is listed against the Arakoda NDA, an ANDA applicant may be required to make a Paragraph IV certification for a generic seeking the protected indication, unless the applicant uses a section viii statement that omits the patented use [3].
Orange Book significance depends on:
- the exact listed patent number;
- the FDA use code;
- the NDA strength and dosage-form entry;
- whether the generic seeks the patented indication; and
- whether the patent remains unexpired and enforceable.
An ANDA applicant could potentially pursue a skinny-label strategy that omits the patented prophylaxis use. That strategy would be difficult if the proposed label, prescribing information, or distribution system still encourages the patented regimen.
What Paragraph IV challenges and generic entry risks exist?
A generic tafenoquine applicant would face two separate issues: product approval and method-of-use patent exposure.
Paragraph IV risk
A Paragraph IV certification would assert that the patent is invalid, unenforceable, or not infringed. The likely attack points include:
- obviousness over earlier tafenoquine malaria-prophylaxis studies;
- lack of written description for the extensive dose and frequency permutations;
- enablement across all claimed doses, populations, and exposure conditions;
- indefiniteness of “potential exposure” and “substantially maintain”;
- indefiniteness or evidentiary difficulty associated with the 80 ng/mL Cmin limitation;
- anticipation by clinical protocols or published prophylaxis regimens; and
- lack of nexus between the claimed pharmacokinetic threshold and the full scope of the dosing ranges.
The patentee would counter that the claims combine a specific loading strategy, weekly maintenance, exposure timing, patient selection, and a clinically meaningful concentration threshold. The 200 mg three-day loading regimen followed by weekly dosing is more vulnerable to prior-art scrutiny if that precise schedule was publicly disclosed before the relevant filing date.
Skinny-label risk
A generic applicant could seek approval for non-patented tafenoquine indications or omit the protected malaria-prophylaxis use. This approach is less effective if the remaining label necessarily directs the same dosing schedule.
For a method-of-use patent, infringement analysis focuses on the approved label and induced-use evidence. A generic label that expressly repeats the 200 mg three-day loading regimen and weekly maintenance schedule would present greater exposure than a label limited to a non-overlapping indication or schedule.
What other patents compete with US 10,342,791?
The tafenoquine patent landscape has several layers:
| Patent layer |
Typical subject matter |
Relevance to US 10,342,791 |
| Core compound patents |
Tafenoquine molecule and chemical derivatives |
Often expired or approaching expiry, depending on family |
| Salt patents |
Tafenoquine succinate and other salts |
Can affect product composition and formulation |
| Formulation patents |
Tablets, solubility, stability, excipients, dosage forms |
May create separate product-level barriers |
| Treatment patents |
P. vivax radical cure or relapse prevention |
Distinct from the claimed P. falciparum prophylaxis |
| Prophylaxis regimen patents |
Loading, weekly dosing, exposure, and post-exposure use |
Directly overlaps this patent |
| Manufacturing patents |
Intermediate chemistry, purification, crystallization |
Can affect supply-chain freedom to operate |
| Regulatory listings |
Orange Book patents tied to approved products |
Determines ANDA certification obligations |
US 10,342,791 is strongest as a regimen patent. It is not, based on the supplied claims, a broad formulation patent. It also does not prevent a competitor from developing another antimalarial, such as atovaquone/proguanil, doxycycline, mefloquine, or a next-generation long-acting antimalarial.
How does tafenoquine compare with competing prophylaxis products?
| Product |
Active ingredient |
Common prophylaxis approach |
Patent risk relative to US 10,342,791 |
| Arakoda |
Tafenoquine succinate |
Three-day loading, weekly dosing, post-exposure dose |
Direct commercial overlap |
| Malarone and generics |
Atovaquone/proguanil |
Daily dosing |
No direct tafenoquine claim overlap |
| Doxycycline products |
Doxycycline |
Daily dosing |
No direct tafenoquine claim overlap |
| Lariam and generics |
Mefloquine |
Weekly dosing |
No direct tafenoquine claim overlap |
| Krintafel |
Tafenoquine succinate |
P. vivax radical cure |
Same active ingredient, different primary indication |
Biosimilar risk is not relevant because tafenoquine is a small-molecule chemical drug. The principal follow-on pathway is an ANDA under section 505(j), not a biosimilar application under section 351(k).
How strong is the patent estate?
US 10,342,791 has meaningful commercial strength because the claimed regimen is close to the approved Arakoda dosing schedule. Its principal strength is label overlap. Its principal weakness is the number of subjective and pharmacokinetic limitations embedded in claim 1.
The estate is stronger when evaluated as a portfolio rather than as a single claim. Relevant protection may come from the combination of:
- the regimen patent;
- tafenoquine salt or formulation patents;
- Orange Book-listed method-of-use patents;
- regulatory exclusivity;
- manufacturing control; and
- commercial know-how concerning patient screening and G6PD testing.
The patent is weaker against a competitor using a materially different regimen, a different indication, a different salt or formulation outside the relevant claims, or a label that omits the patented use.
What patent litigation affects tafenoquine prophylaxis?
The principal litigation risk is an ANDA Paragraph IV case involving a generic tafenoquine product. The supplied record does not identify a specific Paragraph IV notice, district-court complaint, settlement, or final judgment involving US 10,342,791.
A litigation review should distinguish:
- validity challenges to the regimen claims;
- infringement disputes over skinny-label instructions;
- Orange Book listing disputes;
- patent-term and PTA calculations;
- claims directed to tafenoquine succinate or tablet formulation; and
- settlement agreements that may establish a negotiated generic launch date.
A settlement could permit entry before the nominal 2036 patent expiration. Without a public settlement date or court judgment, the patent grant date and nominal term should not be treated as the definitive generic-entry date.
What generic launch scenarios exist?
Three scenarios are commercially plausible:
Full-label ANDA challenge
The applicant seeks the malaria-prophylaxis indication and certifies Paragraph IV against the listed patent. Litigation could trigger a 30-month stay under the Hatch-Waxman framework if statutory conditions are met [3].
Skinny-label launch
The applicant omits the patented prophylaxis use or narrows the dosing instructions. The risk depends on whether the remaining label still encourages the claimed regimen.
Post-expiration launch
The applicant waits until the patent and any additional listed patents or exclusivities expire. This is the lowest litigation-risk path but may leave the generic exposed to other formulation, salt, or manufacturing patents.
Key Takeaways
- US 10,342,791 is a tafenoquine regimen and kit patent, not a broad compound patent.
- Claim 1 covers pre-exposure loading followed by weekly or more frequent exposure dosing.
- The most commercially important regimen is 200 mg daily for three days, 200 mg weekly during exposure, and a post-exposure dose.
- The patent requires an approximately 80 ng/mL Cmin threshold and specified patient characteristics.
- Claims 21 and 22 increase relevance to tafenoquine succinate and other tafenoquine salts.
- Claims 25 through 30 extend protection to post-exposure dosing.
- The patent issued July 9, 2019, with a nominal term endpoint in 2036, subject to USPTO term adjustments.
- Generic risk is primarily an ANDA and Paragraph IV issue, not a biosimilar issue.
- The central validity vulnerabilities are obviousness, enablement, written description, indefiniteness, and proof of the Cmin limitation.
- The central infringement risk is a generic label that reproduces the Arakoda prophylaxis regimen.
FAQs
Does US 10,342,791 cover tafenoquine for P. vivax radical cure?
No. The supplied claims are directed to prevention of symptomatic P. falciparum malaria. A separate patent and regulatory analysis is required for P. vivax radical cure or relapse prevention.
Does the patent cover any tafenoquine tablet?
No. The claims are directed primarily to dosing methods and a kit. A tablet may implicate separate formulation or salt claims, but the patent does not automatically cover every tafenoquine dosage form.
Can a generic sell tafenoquine before 2036?
Possibly, depending on Orange Book listings, Paragraph IV litigation, settlement terms, patent-term adjustments, other patents, and the scope of the generic label. US 10,342,791 alone does not establish an absolute market-entry date.
Is G6PD testing part of the patented method?
The claims require that the subject be G6PD normal. The supplied claims do not expressly require a separate testing step, but patient selection based on G6PD status is a limitation of the claimed method.
Does a daily tafenoquine regimen avoid the patent?
Not necessarily. Claims 3, 9, 11, 14, and 23 expressly include daily or more frequent exposure dosing. A daily regimen must be evaluated against the dose, timing, total weekly amount, patient, and Cmin limitations.
References
- United States Patent No. 10,342,791. (2019). Methods of preventing malaria. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2018). Arakoda (tafenoquine succinate) prescribing information. FDA.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
